The Investment Column: Ellis & Everard
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BACK IN 1997 Ellis & Everard was tipped as the safe play in the chemicals sector, because it wasn't really a chemicals company but the market leader in chemicals distribution. That meant it was less vulnerable to the problems associated with the oversupplied bulk chemicals markets. All very well in theory, but the Asia crisis and recession in Europe pummelled the sector and Ellis's shares coincidentally fell with it, from 319p to 166.5p. They have since recovered to 221.5p. Investors who favour the stock now base their investment case on forthcoming recovery in the global chemicals markets. They should beware.
True, Ellis's sales, margins, and return on capital make it the UK's number one chemicals distributor. It is number four in the world. But tough conditions persist. Ellis's underlying turnover fell from pounds 732m to pounds 720m last year and its cost of sales rose. European sales, dominated by the UK, were particularly weak. Strong US growth partly offset that, but only thanks to last July's acquisition of Performance Polymers.
Economic indicators suggest chemicals prices may recover in a couple of years, but in the near-term any effect will be marginal. In the short- term, Ellis will have to pay for sales growth by making acquisitions. Meanwhile, it reported a weak second half and says trading - ahead of a traditional summer slowdown - is only satisfactory. Analysts expect pre-tax profits of around pounds 33m and earnings of 22p per share this year, putting the shares on a p/e of 10. Given the uncertainties, that's quite fair.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments